FDA Approved: DANTRIUM — Supplemental Application (Par Health USA, LLC)

View source ↗

Summary

FDA approved a supplemental application for Dantrium (dantrolene sodium) from Par Health USA, LLC, under NDA 018264.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Hyperthermia
• Spasticity

Drugs mentioned

• Dantrium (dantrolene)

Snippet

SUPPL AP for DANTRIUM (DANTROLENE SODIUM)